Session Details
Oral Oresentation 4
Fri. Jul 11, 2025 3:30 PM - 4:45 PM JST
Fri. Jul 11, 2025 6:30 AM - 7:45 AM UTC
Fri. Jul 11, 2025 6:30 AM - 7:45 AM UTC
Room Ⅲ(Makuhari Messe Meeting Room 201)
Chair:Kauzo Ohtsuka, Kiichiro Tsuchiya
[O04-01]Efficacy and safety of Mirikizumab versus placebo in East Asian patients with moderately-to-severely active Crohn's disease: a post hoc sub-analysis of the global phase 3 VIVID-1 study
Minhu Chen1, Qian Cao2, Wenjia Liu3, Deliang Liu4, Marc Ferrante5, Tae Oh Kim6, Wentao Luo7, Masaru Tanaka8, Hilde Carlier9, Jiao Yu7, Jiawei Xu7, *Tadakazu Hisamatsu10 (1. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China , 2. Sir Run Run Shaw Hospital, Hangzhou, China, 3. The Second People’s Hospital of Changzhou- the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China, 4. The Second Xiangya Hospital of Central South University, Changsha, China, 5. University Hospitals Leuven, KU Leuven, Leuven, Belgium, 6. Inje University Haeundae Paik Hospital, Busan, South Korea, 7. Eli Lilly and Company, Shanghai, China , 8. Eli Lilly Japan K.K., Kobe, 9. Eli Lilly and Company, Indianapolis, IN, USA, 10. Kyorin University School of Medicine, Tokyo, Japan)
[O04-02]Efficacy of mirikizumab in treating East Asian biologic-failed patients with Crohn's disease: a post hoc subanalysis of the global phase 3 VIVID-1 study
*Minhu Chen1, Baili Chen1, Yan Chen2, Wen Tang3, Zhe Zhang4, Bruce Sands5, Tae Oh Kim6, Wentao Luo7, Masaru Tanaka8, Frederick Durand9, Jiawei Xu7, Tadakazu Hisamatsu10 (1. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2. The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, 3. The Second Affiliated Hospital of Soochow University, Suzhou, China, 4. Shengjing Hospital of China Medical University, Shenyang, China, 5. Icahn School of Medicine at Mount Sinai, New York, NY, USA, 6. Inje University Haeundae Paik Hospital, Busan, South Korea, 7. Eli Lilly and Company, Shanghai, China, 8. Eli Lilly Japan K.K., Kobe, Japan, 9. Eli Lilly and Company, Indianapolis, USA, 10. Kyorin University School of Medicine, Tokyo, Japan)
[O04-03]Efficacy of mirikizumab in comparison to ustekinumab in East Asian patients with moderately-to-severely active Crohn's disease: post hoc sub-analysis of the phase 3 VIVID-1 study
*Minhu Chen1, Xiang Gao2, Vipul Jairath3, Hong Guo4, Zhaotao Li5, Tae Oh Kim6, Wentao Luo7, Masaru Tanaka8, Jiawei Xu7, Frederick Durand9, Tadakazu Hisamatsu10 (1. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2. The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 3. Western University, London, ON, Canada, 4. Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, China, 5. The First People's Hospital of Foshan, Foshan, China, 6. Inje University Haeundae Paik Hospital, Busan, South Korea, 7. Eli Lilly and Company, Shanghai, China , 8. Eli Lilly Japan K.K., Kobe, 9. Eli Lilly and Company, Indianapolis, IN, USA, 10. Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan)
[O04-04]Efficacy and safety of mirikizumab as induction therapy for Chinese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the phase 3 Lucent-1 study
*Zhihua Ran1,2, Jun Shen1, Yan Chen3, Juan Luo4, Yufang Wang5, Xueli Ding6, Hao Fang7, Dan Tang8, Chenxi Qian8, Jiao Yu8 (1. Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 2. Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China, 3. The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China, 4. The First Affiliated Hospital of Kunming Medical University, Kunming, China, 5. West China Hospital of Sichuan University, Chengdu, China, 6. The Affiliated Hospital of Qingdao University, Qingdao, China, 7. Taian City Central Hospital, Taian, China, 8. Eli Lilly and Company, Shanghai, China)
[O04-05]The efficacy and safety of guselkumab as maintenance therapy in Chinese patients with Moderately to Severely Active Ulcerative Colitis: Results of the QUASAR Maintenance Study
*Baili Chen1, Qian Cao2, Yufang Wang3, Shigang Ding4, Naizhong Hu5, Xuan Guo6, Shadi Yarandi7, Jiajia Lu8, Hongyan Zhang7, Minhu Chen1 (1. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P. R. China, 2. Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China, 3. West China Hospital, Sichuan University, Chengdu, P.R. China, 4. Peking University Third Hospital, Beijing, P.R. China, 5. The First Affiliated Hospital of Anhui Medical University, Hefei, P.R. China, 6. Johnson & Johnson, Beijing, P.R. China, 7. Janssen Research & Development, LLC, Spring House, PA, USA, 8. Johnson & Johnson, Shanghai, P.R. China)
[O04-06]The efficacy and safety of guselkumab versus placebo in Chinese patients with moderately to severely active Crohn's disease: Results of the GALAXI 2 and GALAXI 3 Phase 3 Studies
*Baili Chen1, Jie Zhang2, Qian Cao3, Xiang Gao4, Yan Zhang5, Hong Chen6, Yan Chen7, Xuan Guo8, Rian Van Rampelbergh9, Jiajia Lu10, Wilbert van Duijnhoven9, Minhu Chen1 (1. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China, 2. The Second Xiangya Hospital, Central South University, Changsha, P.R. China, 3. Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China, 4. The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China, 5. West China Hospital, Sichuan University, Chengdu, P.R. China, 6. Zhongda Hospital, Southeast University, Nanjing, P.R. China, 7. The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China, 8. Johnson & Johnson, Beijing, P.R. China, 9. Janssen Research & Development, LLC, Antwerp, Belgium, 10. Johnson & Johnson, Shanghai, P.R. China)
[O04-07]Comparative effectiveness of Ustekinumab vs. Infliximab in the Management of Perianal fistulizing Crohn’s disease
*Xiaojun Zhuang1, Mengqi Chen1, Minhu Chen1, Zhirong Zeng1 (1. The First Affiliated Hospital of Sun Yat-sen University)
[O04-08]Short term clinical and endoscopic efficacy of Ustekinumab in Crohn’s disease: Experience from a tertiary care center in Northern India.
*Kshitij Lochab1, Sukrit Sud1, Rajesh Puri1, Randhir Sud1, Amarender S. Puri1 (1. Medanta, The Medicity)
[O04-09]Development and Validation of a Machine Learning Model for Predicting Primary Endoscopic Response to Ustekinumab in Crohn's Disease: A Retrospective Multicenter Cohort Study
*Fan Zhou1, Peng Yan1, Chenchen Wu1, Xin Qian3, Yanping Hao2, Chunyan Peng1, Xiaoqi Zhang1 (1. Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 2. Department of Gastroenterology, The Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, 3. Changzhou Hospital of Traditional Chinese Medicine)
[O04-10]Baseline Serum Immunoproteomic Analysis Predicts Endoscopic Response to Ustekinumab in Patients with Crohn’s Disease
*Chenchen Wu1, Xin Qian2, Jiawen Zheng3, Fan Zhou1 (1. Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 2. Drum Tower Clinical Medical College, Nanjing University of Chinese Medicine, 3. Zhejiang Hospital of Chinese Traditional and Western Medicine)
[O04-11]Long-term efficacy of therapeutic drug monitoring-guided optimization of ustekinumab in Crohn’s disease patients with clinical remission
*Ping an1, hai xia Ren1, Jing wang1, Juan Su1 (1. Department of Gastroenterology, Renmin Hospital of Wuhan University)
[O04-12]Novel Endoluminal Parameters to Predict Primary Loss of Response in Patients with Crohn’s Disease: A National Survey and Multi-center Study
Ruchen Yao1,2, Changsheng Cai1,2, Jie Liang3, Feng Tian4, Xiaocang Cao5, Yue Li6, Yubei Gu7, Qi Feng8, *Jun Shen1,2 (1. Department of Gastroenterology, Renji Hospital, Shanghai Jiaotong University, School of Medicine, 2. NHC Key Laboratory of Digestive Diseases, Shanghai, China, 3. State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Xi'an, China , 4. Department of Gastroenterology, Shengjing Hospital of China Medical University, Sanhao Street No.36, Shenyang, 110004, Liaoning, China, 5. Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin 300070, China, 6. Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China, 7. Department of Gastroenterology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China, 8. Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 160 Pu Jian Road, Shanghai, 200127, China)